Cancer drug costs rise to potentially unsustainable levels

10/24/2013 | New York magazine

Memorial Sloan-Kettering Cancer Center gastrointestinal oncologist Leonard Saltz figured what the cost would be of cancer drug Avastin, which extends survival a median of 42 days, if survival were extended to a year. The cost was $303,000 for a year of life saved, before adding in the costs for the other chemotherapies with which Avastin is given, as well as health care providers, medical equipment, facility expenses and other costs of providing care. He did a similar calculation when Zaltrap was approved and neither he nor his colleagues could find compelling justification for using the drug. This article explores the factors driving the rising and potentially unsustainable cost of cancer drugs.

View Full Article in:

New York magazine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations